Indian health officials say they generally ask for these trials to determine if a vaccine is safe and if it generates an immune response in its own citizens, whose genetic makeup can be different from people in Western nations. Two other vaccines – from AstraZeneca and Bharat Biotech – have been approved. Pfizer claims that its application was supported by data from a global study that showed an overall efficacy rate of 95% with no vaccine-related, serious safety concerns – but they were not willing to allow a new trial to prove it. -GEG
Pfizer Inc has withdrawn an application for emergency-use authorisation of its COVID-19 vaccine in India that it has developed with Germany's BioNTech, the company told the Reuters news agency on Friday.